ARDD 2023: It’s time to make longevity biotechnology credible

ARDD 2023: It's time to make longevity biotechnology credible

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Longevity heavyweights and A-listers pack program for tenth annual Aging Research and Drug Discovery conference.

The largest conference on aging in the biopharmaceutical industry is set to take place 28 August – 1 September 2023 on-site in Copenhagen and online.

Longevity.Technology: The United Nations report that the proportion of people aged over 65 now outnumber children younger than 5. This substantial surge in the elderly populace presents a formidable healthcare challenge for societies across the globe, and it is evident that comprehensive and transformative approaches aimed at mitigating age-related illnesses and vulnerabilities will play a pivotal role in addressing the health and socioeconomic obstacles associated with an aging society. Once again this year, ARDD – now in its tenth year – is set to feature some of the most foremost experts in longevity, who will impart their latest insights on the process of aging and how we target the aging process to maximise lifespan and healthspan.

At ARDD, leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions, making it one of the must-attend events in the longevity space.

The conference will be chaired by Morten Scheibye-Knudsen and Daniela Bakula of The University of Copenhagen and Insilico’s Alex Zhavoronkov, and, as the Ukrainian crisis is still ongoing, just as it did last year, ARDD is offering scientists from Ukraine free places at the conference.

One of this year’s highlights is certain to be the Emerging Tech Workshop on the Monday. The Workshop will explore the harmonic interplay between technologies that are transforming the future of biotechnology, drug discovery and aging research, and features a ‘hands-on journey’ through the realms of blockchain, AI and rapid prototyping with robotics in which participants will take their first guided steps into the metaverse. The Workshop will also explore how blockchain technology enables funding of high-risk biotech research and the role of community owned IP in the future of drug development, as well as demonstrating the power of AI and robotics to accelerate, enhance and scale scientific experiments.

The impressive line-up already boasts more than 70 speakers – too many to name, but the list includes Katrin Andreasson, Nir Barzilai, Joe Betts-LaCroix, Collin Ewald, Richard Faragher, Peter Fedichev, Kristen Fortney, Vadim Gladyshev, Brian Kennedy, James Kirkland, Morten Scheibye-Knudsen, Valter Longo, Andrea Maier, Joan Mannick, Laura Niedernhofer, Marco Quarta, Thomas Rando, Björn Schumacher, Vittorio Sebastiano, David Sinclair, Emma Teeling, Tzipora Strauss, Eric Verdin, Tony Wyss-Coray, Alex Zhavoronkov and Garri Zmudze.

ARDD 2023 is shaping up to be one of this year’s most significant longevity gatherings; as Zhavoronkov tweeted: “If you are thinking about how to engage in aging research in the most credible way possible – go to ARDD.”

Find out more about ARDD 2023 HERE

We’ll be chatting to Alex Zhavoronkov and Morten Scheibye-Knudsen later in the week to find out more about what’s coming up at ARDD 2023 – stay tuned!

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

This field is hidden when viewing the form
AlzeCure banks $10m as Lilly deal closes

The latest longevity science, investment, innovation and insight, delivered every morning.

This field is hidden when viewing the form